The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major
development in the last decade. The indications for ICIs are constantly expanding into new …

Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy. ICIs enhance T cell
activation through various mechanisms and may help reverse the exhausted phenotype of …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …

Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

Immune checkpoint inhibitors (ICI s) block CTLA‐4, PD‐1 and PD‐L1, or other molecules
that control antitumour activities of lymphocytes. These products are associated with a broad …

Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events
(irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not …

In recent years, cancer immunotherapy has made remarkable achievements. Immune
checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the …

ABSTRACT Introduction: Immune checkpoint inhibitors (ICIs) block cytotoxic T lymphocyte
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) …

Background Immune checkpoint inhibitors have revolutionised the oncological landscape in
the last few years. Possible applications include the treatment of hepatocellular carcinoma …

Immune-modulatory therapy, especially with immune-checkpoint inhibitors (ICIs), has
reshaped cancer therapeutics. Immunotherapy is relatively a novel approach that can …